Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

04. Oktober 2021 08:00 ET | Quelle: Orasis Pharmaceuticals

Orasis Pharmaceuticals Appoints Julie Speed as Senior Vice President, Head of Strategy and Marketing to Lead Commercial Growth Plan

HERZLIYA, Israel, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on developing an innovative pharmaceutical solution for the...
26. April 2021 08:00 ET | Quelle: Orasis Pharmaceuticals

Orasis Pharmaceuticals Appoints Industry Veteran, Paul Smith, as President and Chief Operating Officer to Lead the Next Phase of Growth

HERZLIYA, Israel, April 26, 2021 (GLOBE NEWSWIRE) -- Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on developing an innovative pharmaceutical solution for the...
28. Oktober 2020 09:15 ET | Quelle: Orasis Pharmaceuticals

Orasis Pharmaceuticals Announces Initiation of Phase 3 Clinical Studies of Novel Eye Drop Candidate for the Treatment of Presbyopia

HERZLIYA, Israel, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on developing an innovative pharmaceutical solution for the...
10. September 2020 09:30 ET | Quelle: Orasis Pharmaceuticals

Orasis Raises $30 Million to Advance the Clinical Development of Novel Treatment for Presbyopia

HERZLIYA, Israel, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on developing an innovative pharmaceutical solution for the treatment...
10. Oktober 2019 09:30 ET | Quelle: Orasis Pharmaceuticals

Orasis Pharmaceuticals Announces CSF-1 Eye Drop Successfully Met Primary Endpoint in Phase 2b Clinical Study in Presbyopia

HERZLIYA, Israel, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Orasis Pharmaceuticals LTD., a clinical stage pharmaceutical company developing a corrective eye drop for the treatment of presbyopia as an...
27. März 2019 09:14 ET | Quelle: Orasis Pharmaceuticals

Orasis Announces Initiation of Phase 2b Clinical Study of CSF-1 for the Treatment of Presbyopia

HERZLIYA, Israel, March 27, 2019 (GLOBE NEWSWIRE) -- Orasis Pharmaceuticals LTD., a clinical stage pharmaceutical company developing a corrective eye drop for the treatment of presbyopia as an...
27. November 2018 08:00 ET | Quelle: Orasis Pharmaceuticals

Orasis Announces Appointments of Richard L. Lindstrom, Eric D. Donnenfeld, and John Berdahl to its Scientific Advisory Board

HERZLIYA, Israel, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Orasis Pharmaceuticals LTD., a clinical stage pharmaceutical company developing a corrective eye drop for the treatment of presbyopia as an...
22. Oktober 2018 08:00 ET | Quelle: Orasis Pharmaceuticals

Orasis Announces the Appointment of Jeffry Weinhuff as Chairman of the Board of Directors

HERZLIYA, Israel, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Orasis Pharmaceuticals LTD. a clinical-stage pharmaceutical company developing a corrective eye drop for the treatment of presbyopia as an...
05. Juni 2018 09:30 ET | Quelle: Orasis Pharmaceuticals

Orasis Pharmaceuticals Closes $13 Million Series B Financing

HERZLIYA, Israel, June 05, 2018 (GLOBE NEWSWIRE) -- Orasis Pharmaceuticals LTD., a privately-held, clinical-stage pharmaceutical company focused on developing an innovative eye drop for the...